IP Library › Granted Patent US 10,513,723
Granted Patent B2
US 10,513,723 · App. 15/111,470 · Granted Dec 24, 2019

Decreasing ornithine production to decrease high mannose glycoform content of recombinant proteins

Inventors: Sohye Kang (Camarillo, CA); Chung Huang, Jr. (Newbury Park, CA); Hedieh Barkhordarian (Moorpark, CA); Pavel Bondarenko (Thousand Oaks, CA); Zhongqi Zhang (Thousand Oaks, CA)
C12P21/005C07K14/52C07K16/00C12N1/38C12N5/0682C07K2317/14C07K2317/41C12N2500/32C12N2500/33C12N2500/46C12N2500/90C12N2510/02C12N2521/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,513,723
App. No.
15/111,470
Granted
Dec 24, 2019
Kind
B2
Abstract

The present invention relates to a method for manipulating the high mannose glycoform content of recombinant glycoproteins by regulating ornithine metabolism during cell culture.

Claims (23)

1. A method for decreasing the high mannose glycoform content of a recombinant protein comprising culturing a host cell expressing the recombinant protein in a cell culture comprising an arginase inhibitor, wherein ornithine production in the host cell is decreased when compared to the host cell expressing the recombinant protein cultured in a cell culture lacking the arginase inhibitor, and

the recombinant protein has a decreased high mannose glycoform content than when the recombinant protein is expressed in the cell culture lacking the arginase inhibitor.

2. The method according to claim 1 , wherein the arginase inhibitor is selected from the group consisting of N G -hydroxy-L-arginine monoacetate, Nω-hydroxy-nor-arginine diacetate, BEC (S-(2-boronoethyl)-1-cysteine) and DL-a-Difluoromethylornithine.

3. The method according to claim 1 , wherein the arginase inhibitor is BEC (S-(2-boronoethyl)-l-cysteine).

4. The method according to claim 1 , wherein the arginase inhibitor is DL-a-Difluoromethylornithine.

5. The method according to claim 1 , wherein the arginase inhibitor is:

(a) N G -hydroxy-L-arginine monoacetate, having a concentration of 1 μM, 10 μM or 20 μM;

(b) Nω-hydroxy-nor-arginine diacetate, having a concentration of 10 μM or 20 μM;

(c) BEC (S-(2-boronoethyl)-l-cysteine), having a concentration of 1 μM, 10 μM, 20 μM or 0.5 mM; or

(d) DL-α-difluoromethylornithine, having a concentration of 1 μM, 10 μM, 20 μM, 1 mM or 2 mM.

6. The method according to claim 5 , wherein concentration of the arginase inhibitor is selected from the group consisting of at least 10 μM, from 10 μM to 2 mM, 0.5 mM to 2 mM, 0.5 mM to 1 mM and 1 mM to 2 mM.

7. The method according to claim 5 , wherein the arginase inhibitor is selected from the group consisting of Nω-hydroxy-nor-arginine diacetate, BEC (S-(2-boronoethyl)-1-cysteine); and DL-α-difluoromethylornithine, wherein the concentration of the arginase inhibitor is 10 μM.

8. The method according to claim 5 , wherein the arginase inhibitor is BEC (S-(2-boronoethyl)-l-cysteine), wherein the concentration of the arginase inhibitor is 0.5 mM.

9. The method according to claim 5 , wherein the arginase inhibitor is DL-α-difluoromethylornithine, wherein the concentration of the arginase inhibitor is 1 mM.

10. The method according to claim 5 , wherein the arginase inhibitor is DL-α-difluoromethylornithine, wherein the concentration of the arginase inhibitor is 2 mM.

11. A method of decreasing high mannose glycoform content of a recombinant protein comprising culturing a host cell expressing the recombinant protein in a cell culture comprising spermine, wherein ornithine production in the host cell is decreased when compared to the host cell expressing the recombinant protein cultured in a cell culture with a greater concentration of spermine and

the recombinant protein has a decreased high mannose glycoform content than the recombinant protein expressed by the cell culture having a greater concentration of spermine.

12. The method according to claim 11 , wherein the concentration of spermine is 35 μM or less.

13. The method according to claim 11 , wherein the concentration of spermine is 7 μM to 35 μM.

14. The method according to claim 11 , wherein the concentration of spermine is 27 μM to 35 μM.

15. The method according to claim 11 , wherein the concentration of spermine is 7 μM to 27 μM.

16. The method according to claim 11 , wherein the concentration of spermine is 35 μM.

17. The method according to claim 11 , wherein the concentration of spermine is 27 μM.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2019
From: BONDARENKO, PAVEL; ZHANG, ZHONGQI
To: AMGEN INC.
Reel/Frame 050936/0094 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2017
From: KANG, SOHYE; HUANG, CHUNG, JR.; BARKHORDARIAN, HEDIEH
To: AMGEN INC.
Reel/Frame 041084/0756 →
Continuity (2)
Provisional Application 61926481 · Jan 13, 2014
Related Publication 20160333385A1 · Nov 17, 2016